Janssen Pharmaceuticals Releases a 2016 U.S. Transparency Report
The 5 Stages of COVID-19 Vaccine Development: What You Need to Know About How a Clinical Trial WorksDid you like reading this story? Click the heart to show your love.
Johnson & Johnson Signs a Historic Pledge to Uphold the Integrity of the Scientific Process in Developing an Investigational COVID-19 VaccineClick the heart to show your support of this pledge.
The Impact of COVID-19 on a Company: 6 Questions for the Chief Financial Officer of Johnson & JohnsonDid you like reading this story? Click the heart to show your love.
Johnson & Johnson has a legacy of leadership when it comes to transparency. And the Janssen Pharmaceutical Companies of Johnson & Johnson recognize that consumers in the U.S. are particularly concerned about the high cost of healthcare these days.
That's why the company just released a 2016 U.S. Transparency Report that includes information on pricing and other business practices, covering everything from discovery to the commercialization of pharmaceuticals.
"Our hope is that this report will address questions people may have, and that it will lead to more discussion about how we can work together to move toward a more value-based healthcare system—one that delivers what we all want: greater access to care at a more manageable cost, and, most importantly, better health for us all," says, Company Group Chairman, Pharmaceuticals, The Americas.
Watch this video of Taubert to learn more about the 2016 U.S. Transparency Report and how it can help better inform consumers.